Learning Center
Plans & pricing Sign in
Sign Out



                                                                   VisualSonics: Shailja Tewari
                                                          SonoSite: Lisa Fritzky (425) 951-1375



The Vevo LAZR System Debuts at the American Association of Cancer Research April 3-6,
                                 Orlando, Florida

TORONTO, Canada – March x, 2011 – VisualSonics Inc., a leader in real time, in vivo, high-
resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc.,
(Nasdaq:Sono), today announced the launch of the Vevo LAZR Photoacoustics Imaging
system for the advancement of cancer research in the pre-clinical imaging market. This
revolutionary technology combines the sensitivity of optical imaging with the resolution and
depth penetration of high-frequency ultrasound, enabling researchers to study cancer in its
earliest stages of progression and detection and evaluation of tumor growth. For the first time,
researchers will be able to observe tumor biology, measure hypoxia (oxygen levels), evaluate
changes in blood flow, and quantify data with unique software solutions in vivo and in real-time.
Ultimately, this technology provides researchers with never-before-seen insights into the
development of effective therapeutics for treating cancer. The Vevo LAZR photoacoustics
system debuts at the American Association of Cancer Research on April 3-6th at the Orange
County Convention Center, Orlando, Florida.
After two years of research and development, images and data generated by the Vevo LAZR
system were presented at the World Molecular Imaging Conference (WMIC) in Kyoto, Japan in
September 2010 where the system received strong feedback from prestigious organizations and
research institutes from around the globe. One of the first scientific users of the Vevo LAZR
system, David A. Jaffray, Ph.D, Head, Radiation Physics - Ontario Cancer Institute / Princess
Margaret Hospital commented, “Advanced imaging technologies like VisualSonics' Vevo
LAZR photoacoustics system allow our scientists to see into the processes that sustain a disease
like cancer. With this knowledge, we can design the next generation of therapies.”

“The Vevo LAZR photoacoustics system is the future of pre-clinical research,” said Anil
Amlani, VisualSonics’ President and CEO. “Building on our high-frequency ultrasound
technology, which is now considered a gold standard for many in vivo applications, the Vevo
LAZR photoacoustics system offers the unique capability to non-invasively capture real-time,
high resolution data that is unavailable and unparalleled to any other in vivo anatomical or
molecular imaging technology.”

The platform of the Vevo LAZR system integrates proprietary imaging capabilities that will
further improve a researcher’s overall experience and will set new standards for performance in
pre-clinical research. The system’s co-registration function is an essential feature that will aid in
the discovery and assessment of novel drug therapies. With the ability to capture high-resolution
images with high-frequency ultrasound, the co-registration function enables researchers to
simultaneously superimpose a photoacoustic signal over the ultrasound image, allowing for the
assessment and quantification of oxygen saturation and blood levels in tissues and organs. The
Vevo LAZR system also includes an automated multispectral imaging algorithm that provides
researchers with the flexibility of selecting multiple imaging wavelengths to optimize the
visualization of contrast agents, such as nanoparticles and dyes.

Mr. Amlani continued, “We believe the Vevo LAZR system will have a strong impact on the
discovery of new cancer therapies in the pre-clinical market space and that we will see a
translation of these discoveries into practical applications in humans. With a healthy set of pre-
ordered systems, we are anticipating strong product demand.”
“The launch of this ‘new to the world’ technology keeps VisualSonics at the forefront of imaging
advancements for life-sciences research,” said Kevin M. Goodwin, SonoSite President and CEO.
“We are excited that SonoSite and VisualSonics have joined forces to innovate and deliver new
breakthrough imaging technologies and we are pleased with the initial customer demand for the
new product.”

The Vevo LAZR system supports VisualSonics continuous efforts to provide researchers with
innovative solutions to improving pre-clinical research. The core of the Vevo LAZR technology
is the LZ® Series integrated fiber-optic linear array transducers with microbeamforming
technology. Harnessing the sensitivity of 256 active elements, the LZ Series transducers provides
clear and high-resolution images - in both 2D and 3D modes. Applications for the Vevo LAZR
system range from lymph node imaging, study of hemoglobin and oxygen saturation, and
targeted imaging of tumor biomarkers. In addition to cancer biology, this cutting-edge imaging
system will benefit other areas of research such as diabetes, neurosciences, as well as
developmental and reproductive biology.

Researchers are invited to experience a demonstration of the Vevo LAZR system by visiting
VisualSonics at booth #2171 at AACR.

About VisualSonics

VisualSonics is the world leader in real time, in vivo, high-resolution micro imaging systems
designed specifically for preclinical research and a wholly-owned subsidiary of SonoSite, Inc.
(Nasdaq:Sono). The Company’s cutting edge technologies allow researchers at the world’s most
prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct
research in cardiovascular, cancer, neurobiology and developmental biology areas. The micro
imaging technologies support research applications that include genetic research, phenotypic
studies and drug development. VisualSonics micro imaging platforms combine high-resolution,
real time in vivo imaging at reasonable cost with ease-of-use and quantifiable results.

About SonoSite
SonoSite, Inc. ( is the innovator and world leader in bedside and point-
of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound
technology and impedance cardiography equipment. Headquartered near Seattle, the
company is represented by fourteen subsidiaries and a global distribution network in over
100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound
across the clinical spectrum by cost-effectively bringing high-performance ultrasound to
the point of patient care.

To top